

# **Europe Biosimilars Market Forecast to 2030 - Regional Analysis By Disease Indication (Cancer, Diabetes, Autoimmune Disease, and Other Disease Indication), Route of Administration (Intravenous, Subcutaneous, and Others), Drug Class (Granulocyte Colony-Stimulating Factor, Insulin, TNF Blockers and Monoclonal Antibodies, and Others), Distribution Channel (Hospital Pharmacies, Compounding Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region**

<https://marketpublishers.com/r/E146EE1D1C50EN.html>

Date: August 2023

Pages: 205

Price: US\$ 3,000.00 (Single User License)

ID: E146EE1D1C50EN

## **Abstracts**

The Europe biosimilars market is expected to grow from US\$ 10,344.86 million in 2022 to US\$ 1,15,125.91 million by 2030; it is estimated to grow at a CAGR of 35.1% from 2022 to 2030.

The report highlights trends prevailing in the market and factors driving the market growth. The market growth is attributed to the increasing prevalence of chronic diseases and rising approvals of biosimilars. Additionally, collaborations for biosimilars and clinical trials is likely to emerge as a significant trend in the market during the forecast period. However, high cost involvement and complexities in biosimilar product manufacturing hinders market growth during the forecast period 2022-2030.

Collaborations for Biosimilars and Clinical Trials Drives the Europe Biosimilars Market

Joint ventures and other collaboration models will help biosimilar medicine

manufacturers maintain a competitive edge over rivals in the market in the coming years.

By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding.

Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer.

There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. In a sizeable market such as Europe, which has significant country-level diversity in healthcare policies and market dynamics, access to local knowledge obtained through such collaborations can also prove invaluable.

The immense potential of the biosimilars market has led to many recent, high-profile collaborations. A few instances are given below:

In June 2023, Samsung Biologics announced a strategic partnership with Pfizer for the long-term commercial manufacturing of Pfizer's multi-product portfolio. The agreement aims that Samsung Biologics will offer Pfizer additional capacity for large-scale manufacturing of a multi-product biosimilar portfolio encompassing oncology, inflammation, and immunology.

In May 2023, Sandoz, a Novartis division, announced a biosimilar collaboration with Evotec Biologics. The agreement covers developing and manufacturing multiple biosimilar medicines intended for rapid development and the subsequent manufacturing of multiple biosimilars. The development of biosimilars at the Evotec Biologics facility will ramp up under the collaboration in the next 12–18 months.

Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.

## Patent Expiry of Blockbuster Biologics Offers Lucrative Market Opportunity

Biologics represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. However, patents for originator biologics are expected to expire in the coming years.

Estimated patent and exclusivity expiry dates for best-selling biologics are given in the following table .

### Biologics Expiry Month & Years

Avastin January 2022

Cyramza May 2023

Adcetris August 2023

Abthrax October 2024

Gazyva/Gazyvaro November 2024

Darzalex May 2026

Ocrevus April 2027

Emgality September 2028

Hemlibra February 2028

Llumetri March 2028

Imfinzi September 2028

Mylotarg April 2028

Imfinzi September 2028

Mylotarg April 2028

Sylvant July 2034

Source: Generics and Biosimilars Initiative (GaBI) Journal

The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the biosimilar market during the forecast period.

Germany holds largest market share for the Europe biosimilars market from 2022-2030. Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare community. Healthcare professionals can treat more patients with high-quality biologics while reducing spending. For example, in Germany, according to Sandoz, the number of daily therapeutic doses of an anti-TNF medicine increased by 29% (from 17.18 to 22.18 million) after introducing biosimilars in 2022.

Germany has achieved acceptance of biosimilars with payers, providers, and patients as an integral part of appropriate medicine use. There is full reimbursement from a price set by the company, including immediate patient access to biosimilars. The structure of hospital tendering by multiple buying groups and separate hospital chains allows for competition among manufacturers to be maintained in Germany. For instance, in November 2018, the German Health Ministry introduced a draft bill on safety in the supply of pharmaceuticals. The Gesetz für Mehr Sicherheit in der Arzneimittelversorgung (GSAV) bill aims to provide a legal framework for the automatic substitution of biosimilars by pharmacists in Germany.

Due to the huge potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. As few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. Additionally, in Germany, a law passed in 2019 foresees the automatic substitution of biosimilars in pharmacies beginning in 2022, provided the Federal Joint Committee (the highest decision-making body of the self-governance of health insurers and providers) has determined the interchangeability of the medicines in question, and the prescribing physician has not explicitly excluded it. Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to grow.

Various organic and inorganic strategies are adopted by companies in the Europe biosimilars market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few of the significant developments by key players in the Europe biosimilars market are listed below.

International Diabetes Federation, European Medicine Agency, Centers for Disease Control and Prevention, Chinese Clinical Oncology, National Comprehensive Care Network are a few of the major primary and secondary sources referred to while preparing the report on the Europe biosimilars market.

## Contents

### **1. INTRODUCTION**

- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation

### **2. EUROPE BIOSIMILARS MARKET – KEY TAKEAWAYS**

### **3. RESEARCH METHODOLOGY**

- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research

### **4. EUROPE BIOSIMILARS MARKET – MARKET LANDSCAPE**

- 4.1 Overview
  - 4.1.1 Europe PEST Analysis
- 4.2 Actual Market Price/Net Price
  - 4.2.1 France
  - 4.2.2 Germany
  - 4.2.3 Italy
  - 4.2.4 Spain
  - 4.2.5 UK

### **5. EUROPE BIOSIMILARS MARKET**

- 5.1 Market Drivers
  - 5.1.1 Increasing Prevalence of Chronic Diseases
  - 5.1.2 Rising Approvals of Biosimilars
- 5.2 Market Restraints
  - 5.2.1 High Cost Involvement and Complexities in Biosimilar Product Manufacturing
- 5.3 Market Opportunities
  - 5.3.1 Patent Expiry of Blockbuster Biologics
- 5.4 Future Trends
  - 5.4.1 Collaborations for Biosimilars and Clinical Trials
- 5.5 Impact analysis

## **6. EUROPE BIOSIMILARS MARKET – REGIONAL ANALYSIS**

### 6.1 Europe Biosimilars Market Revenue Forecast and Analysis

## **7. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2030 – BY DISEASE INDICATION**

### 7.1 Overview

### 7.2 Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)

### 7.3 Cancer

#### 7.3.1 Overview

#### 7.3.2 Cancer: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

### 7.4 Diabetes

#### 7.4.1 Overview

#### 7.4.2 Diabetes: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

### 7.5 Autoimmune Diseases

#### 7.5.1 Overview

#### 7.5.2 Autoimmune Diseases: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

### 7.5.3 Psoriasis

#### 7.5.3.1 Overview

#### 7.5.4 Psoriasis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

### 7.5.5 Arthritis

#### 7.5.5.1 Overview

#### 7.5.6 Arthritis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

### 7.5.7 Others

#### 7.5.7.1 Overview

#### 7.5.7.2 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

### 7.6 Other Disease Indication

#### 7.6.1 Overview

#### 7.6.2 Other Disease Indication: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

## **8. EUROPE BIOSIMILARS MARKET ANALYSIS AND FORECASTS TO 2028 – BY ROUTE OF ADMINISTRATION**

## 8.1 Overview

### 8.2 Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)

#### 8.3 Intravenous

##### 8.3.1 Overview

##### 8.3.2 Intravenous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

#### 8.4 Subcutaneous

##### 8.4.1 Overview

##### 8.4.2 Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

#### 8.5 Others

##### 8.5.1 Overview

##### 8.5.2 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

## **9. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2030 – BY DRUG CLASS**

### 9.1 Overview

#### 9.2 Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)

#### 9.3 Granulocyte Colony-Stimulating Factor

##### 9.3.1 Overview

##### 9.3.2 Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

#### 9.4 Insulin

##### 9.4.1 Overview

##### 9.4.2 Insulin: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

#### 9.5 TNF Blockers and Monoclonal Antibodies

##### 9.5.1 Overview

##### 9.5.2 TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

#### 9.6 Others

##### 9.6.1 Overview

##### 9.6.2 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

## **10. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2030 – BY DISTRIBUTION CHANNEL**

### 10.1 Overview



- 10.2 Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
- 10.3 Endocrinologists
  - 10.3.1 Overview
- 10.4 Immunologists
  - 10.4.1 Overview
- 10.5 Rheumatologists
  - 10.5.1 Overview
- 10.6 Oncologists
  - 10.6.1 Overview
- 10.7 Dermatologists
  - 10.7.1 Overview
- 10.8 Retina Compounding
  - 10.8.1 Overview
- 10.9 Others
  - 10.9.1 Overview
- 10.10 Hospital Pharmacies
  - 10.10.1 Overview
  - 10.10.2 Hospital Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)
    - 10.10.3 Endocrinologists
      - 10.10.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)
    - 10.10.4 Immunologists
      - 10.10.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)
    - 10.10.5 Rheumatologists
      - 10.10.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)
    - 10.10.6 Oncologists
      - 10.10.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)
    - 10.10.7 Dermatologists
      - 10.10.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)
    - 10.10.8 Retina Specialists
      - 10.10.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)
    - 10.10.9 Others

10.10.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.11 Compounding Pharmacies

10.11.1 Overview

10.11.2 Compounding Pharmacies : Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.11.3 Endocrinologists

10.11.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.11.4 Immunologists

10.11.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.11.5 Rheumatologists

10.11.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.11.6 Oncologists

10.11.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.11.7 Dermatologists

10.11.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.11.8 Retina Specialists

10.11.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.11.9 Others

10.11.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.12 Retail Pharmacies

10.12.1 Overview

10.12.2 Retail Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.12.3 Endocrinologists

10.12.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.12.4 Immunologists

10.12.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.12.5 Rheumatologists

10.12.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030

(US\$ Million)

10.12.6 Oncologists

10.12.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030

(US\$ Million)

10.12.7 Dermatologists

10.12.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030

(US\$ Million)

10.12.8 Retina Specialists

10.12.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.12.9 Others

10.12.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.13 Online Pharmacies

10.13.1 Overview

10.13.2 Online Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.13.3 Endocrinologists

10.13.3.1 Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.13.4 Immunologists

10.13.4.1 Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.13.5 Rheumatologists

10.13.5.1 Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.13.6 Oncologists

10.13.6.1 Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.13.7 Dermatologists

10.13.7.1 Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.13.8 Retina Specialists

10.13.8.1 Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

10.13.9 Others

10.13.9.1 Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

## **11. EUROPE BIOSIMILARS MARKET – REVENUE AND FORECAST TO 2030 – GEOGRAPHIC ANALYSIS**

### 11.1 Europe Biosimilars Market, Revenue and Forecast to 2030

#### 11.1.1 Overview

#### 11.1.2 Europe Biosimilars Market Revenue and Forecast to 2030 (US\$ Mn)

##### 11.1.2.1 Europe Biosimilars Market, by Disease Indication

##### 11.1.2.2 Europe Biosimilars Market, by Autoimmune Diseases

##### 11.1.2.3 Europe Biosimilars Market, by Route of Administration

##### 11.1.2.4 Europe Biosimilars Market, by Drug Class

##### 11.1.2.5 Europe Biosimilars Market, by Distribution Channel

##### 11.1.2.6 Europe Biosimilars Market, by Hospital Pharmacies

##### 11.1.2.7 Europe Biosimilars Market, by Compounding Pharmacies

##### 11.1.2.8 Europe Biosimilars Market, by Retail Pharmacies

##### 11.1.2.9 Europe Biosimilars Market, by Online Pharmacies

##### 11.1.2.10 Europe Biosimilars Market by Country

##### 11.1.2.10.1 Germany

###### 11.1.2.10.1.1 Overview

###### 11.1.2.10.1.2 Germany Biosimilars Market Revenue and Forecast to 2030 (US\$ Mn)

###### 11.1.2.10.1.2.1 Germany Biosimilars Market, by Disease Indication

###### 11.1.2.10.1.2.2 Germany Biosimilars Market, by Autoimmune Diseases

###### 11.1.2.10.1.2.3 Germany Biosimilars Market, by Route of Administration

###### 11.1.2.10.1.2.4 Germany Biosimilars Market, by Drug Class

###### 11.1.2.10.1.2.5 Germany Biosimilars Market, by Distribution Channel

###### 11.1.2.10.1.2.6 Germany Biosimilars Market, by Hospital Pharmacies

###### 11.1.2.10.1.2.7 Germany Biosimilars Market, by Compounding Pharmacies

###### 11.1.2.10.1.2.8 Germany Biosimilars Market, by Retail Pharmacies

###### 11.1.2.10.1.2.9 Germany Biosimilars Market, by Online Pharmacies

##### 11.1.2.10.2 UK

###### 11.1.2.10.3 Overview

###### 11.1.2.10.3.1 UK Biosimilars Market Revenue and Forecast to 2030 (US\$ Mn)

###### 11.1.2.10.3.1.1 UK Biosimilars Market, by Disease Indication

###### 11.1.2.10.3.1.2 UK Biosimilars Market, by Autoimmune Diseases

###### 11.1.2.10.3.1.3 UK Biosimilars Market, by Route of Administration

###### 11.1.2.10.3.1.4 UK Biosimilars Market, by Drug Class

###### 11.1.2.10.3.1.5 UK Biosimilars Market, by Distribution Channel

###### 11.1.2.10.3.1.6 UK Biosimilars Market, by Hospital Pharmacies

###### 11.1.2.10.3.1.7 UK Biosimilars Market, by Compounding Pharmacies

###### 11.1.2.10.3.1.8 UK Biosimilars Market, by Retail Pharmacies

- 11.1.2.10.3.1.9 UK Biosimilars Market, by Online Pharmacies
- 11.1.2.10.4 France
  - 11.1.2.10.4.1 Overview
  - 11.1.2.10.4.2 France Biosimilars Market Revenue and Forecast to 2030 (US\$ Mn)
    - 11.1.2.10.4.2.1 France Biosimilars Market, by Disease Indication
    - 11.1.2.10.4.2.2 France Biosimilars Market, by Autoimmune Diseases
    - 11.1.2.10.4.2.3 France Biosimilars Market, by Route of Administration
    - 11.1.2.10.4.2.4 France Biosimilars Market, by Drug Class
    - 11.1.2.10.4.2.5 France Biosimilars Market, by Distribution Channel
    - 11.1.2.10.4.2.6 France Biosimilars Market, by Hospital Pharmacies
    - 11.1.2.10.4.2.7 France Biosimilars Market, by Compounding Pharmacies
    - 11.1.2.10.4.2.8 France Biosimilars Market, by Retail Pharmacies
    - 11.1.2.10.4.2.9 France Biosimilars Market, by Online Pharmacies
  - 11.1.2.10.5 Italy
    - 11.1.2.10.5.1 Overview
    - 11.1.2.10.5.2 Italy Biosimilars Market Revenue and Forecast to 2030 (US\$ Mn)
      - 11.1.2.10.5.2.1 Italy Biosimilars Market, by Disease Indication
      - 11.1.2.10.5.2.2 Italy Biosimilars Market, by Autoimmune Diseases
      - 11.1.2.10.5.2.3 Italy Biosimilars Market, by Route of Administration
      - 11.1.2.10.5.2.4 Italy Biosimilars Market, by Drug Class
      - 11.1.2.10.5.2.5 Italy Biosimilars Market, by Distribution Channel
      - 11.1.2.10.5.2.6 Italy Biosimilars Market, by Hospital Pharmacies
      - 11.1.2.10.5.2.7 Italy Biosimilars Market, by Compounding Pharmacies
      - 11.1.2.10.5.2.8 Italy Biosimilars Market, by Retail Pharmacies
      - 11.1.2.10.5.2.9 Italy Biosimilars Market, by Online Pharmacies
    - 11.1.2.10.6 Spain
      - 11.1.2.10.6.1 Overview
      - 11.1.2.10.6.2 Spain Biosimilars Market Revenue and Forecast to 2030 (US\$ Mn)
        - 11.1.2.10.6.2.1 Spain Biosimilars Market, by Disease Indication
        - 11.1.2.10.6.2.2 Spain Biosimilars Market, by Autoimmune Diseases
        - 11.1.2.10.6.2.3 Spain Biosimilars Market, by Route of Administration
        - 11.1.2.10.6.2.4 Spain Biosimilars Market, by Drug Class
        - 11.1.2.10.6.2.5 Spain Biosimilars Market, by Distribution Channel
        - 11.1.2.10.6.2.6 Spain Biosimilars Market, by Hospital Pharmacies
        - 11.1.2.10.6.2.7 Spain Biosimilars Market, by Compounding Pharmacies
        - 11.1.2.10.6.2.8 Spain Biosimilars Market, by Retail Pharmacies
        - 11.1.2.10.6.2.9 Spain Biosimilars Market, by Online Pharmacies
      - 11.1.2.10.7 Rest of Europe
        - 11.1.2.10.7.1 Overview

#### 11.1.2.10.7.2 Rest of Europe Biosimilars Market Revenue and Forecast to 2030 (US\$ Mn)

- 11.1.2.10.7.2.1 Rest of Europe Biosimilars Market, by Disease Indication
- 11.1.2.10.7.2.2 Rest of Europe Biosimilars Market, by Autoimmune Diseases
- 11.1.2.10.7.2.3 Rest of Europe Biosimilars Market, by Route of Administration
- 11.1.2.10.7.2.4 Rest of Europe Biosimilars Market, by Drug Class
- 11.1.2.10.7.2.5 Rest of Europe Biosimilars Market, by Distribution Channel
- 11.1.2.10.7.2.6 Rest of Europe Biosimilars Market, by Hospital Pharmacies
- 11.1.2.10.7.2.7 Rest of Europe Biosimilars Market, by Compounding Pharmacies
- 11.1.2.10.7.2.8 Rest of Europe Biosimilars Market, by Retail Pharmacies
- 11.1.2.10.7.2.9 Rest of Europe Biosimilars Market, by Online Pharmacies

## **12. PRE AND POST COVID-19 IMPACT**

### 12.1 Pre and Post COVID-19 Impact

## **13. BIOSIMILARS MARKET – INDUSTRY LANDSCAPE**

- 13.1 Overview
- 13.2 Growth Strategies in Biosimilars Market
- 13.3 Inorganic Growth Strategies
  - 13.3.1 Overview
- 13.4 Organic Growth Strategies
  - 13.4.1 Overview

## **14. COMPANY PROFILES**

- 14.1 Amgen Inc
  - 14.1.1 Key Facts
  - 14.1.2 Business Description
  - 14.1.3 Products and Services
  - 14.1.4 Financial Overview
  - 14.1.5 SWOT Analysis
  - 14.1.6 Key Developments
- 14.2 Celltrion Inc
  - 14.2.1 Key Facts
  - 14.2.2 Business Description
  - 14.2.3 Products and Services
  - 14.2.4 Financial Overview

- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
- 14.3 Sanofi SA
  - 14.3.1 Key Facts
  - 14.3.2 Business Description
  - 14.3.3 Products and Services
  - 14.3.4 Financial Overview
  - 14.3.5 SWOT Analysis
- 14.4 Biocon Ltd
  - 14.4.1 Key Facts
  - 14.4.2 Business Description
  - 14.4.3 Products and Services
  - 14.4.4 Financial Overview
  - 14.4.5 SWOT Analysis
  - 14.4.6 Key Developments
- 14.5 Samsung Bioepis Co Ltd
  - 14.5.1 Key Facts
  - 14.5.2 Business Description
  - 14.5.3 Products and Services
  - 14.5.4 Financial Overview
  - 14.5.5 SWOT Analysis
  - 14.5.6 Key Developments
- 14.6 Eli Lilly and Co
  - 14.6.1 Key Facts
  - 14.6.2 Business Description
  - 14.6.3 Products and Services
  - 14.6.4 Financial Overview
  - 14.6.5 SWOT Analysis
  - 14.6.6 Key Developments
- 14.7 Sandoz AG
  - 14.7.1 Key Facts
  - 14.7.2 Business Description
  - 14.7.3 Products and Services
  - 14.7.4 Financial Overview
  - 14.7.5 SWOT Analysis
  - 14.7.6 Key Developments
- 14.8 Teva Pharmaceutical Industries Ltd
  - 14.8.1 Key Facts
  - 14.8.2 Business Description



- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
- 14.9 Pfizer Inc
  - 14.9.1 Key Facts
  - 14.9.2 Business Description
  - 14.9.3 Products and Services
  - 14.9.4 Financial Overview
  - 14.9.5 SWOT Analysis
  - 14.9.6 Key Developments
- 14.10 Dr. Reddy's Laboratories Ltd
  - 14.10.1 Key Facts
  - 14.10.2 Business Description
  - 14.10.3 Products and Services
  - 14.10.4 Financial Overview
  - 14.10.5 SWOT Analysis
  - 14.10.6 Key Developments

## **15. APPENDIX**

- 15.1 About The Insight Partners
- 15.2 Glossary of Terms



## List Of Tables

### LIST OF TABLES

Table 1. Comparison Between Different Drug Developments

Table 2. Europe Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn) – Disease Indication

Table 3. Europe Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn) – Autoimmune Diseases

Table 4. Europe Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Route of Administration

Table 5. Europe Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Drug Class

Table 6. Europe Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Distribution Channel

Table 7. Europe Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Hospital Pharmacies

Table 8. Europe Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Compounding Pharmacies

Table 9. Europe Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Retail Pharmacies

Table 10. Europe Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Online Pharmacies

Table 11. Germany Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn) – Disease Indication

Table 12. Germany Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn) – Autoimmune Diseases

Table 13. Germany Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Route of Administration

Table 14. Germany Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Drug Class

Table 15. Germany Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Distribution Channel

Table 16. Germany Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Hospital Pharmacies

Table 17. Germany Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Compounding Pharmacies

Table 18. Germany Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Retail Pharmacies

Table 19. Germany Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Online Pharmacies

Table 20. UK Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn) – Disease Indication

Table 21. UK Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn) – Autoimmune Diseases

Table 22. UK Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Route of Administration

Table 23. UK Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Drug Class

Table 24. UK Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Distribution Channel

Table 25. UK Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Hospital Pharmacies

Table 26. UK Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Compounding Pharmacies

Table 27. UK Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Retail Pharmacies

Table 28. UK Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Online Pharmacies

Table 29. France Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn) – Disease Indication

Table 30. France Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn) – Autoimmune Diseases

Table 31. France Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Route of Administration

Table 32. France Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Drug Class

Table 33. France Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Distribution Channel

Table 34. France Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Hospital Pharmacies

Table 35. France Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Compounding Pharmacies

Table 36. France Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Retail Pharmacies

Table 37. France Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Online Pharmacies

Table 38. Italy Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn) – Disease

## Indication

Table 39. Italy Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn) – Autoimmune Diseases

Table 40. Italy Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Route of Administration

Table 41. Italy Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Drug Class

Table 42. Italy Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Distribution Channel

Table 43. Italy Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Hospital Pharmacies

Table 44. Italy Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Compounding Pharmacies

Table 45. Italy Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Retail Pharmacies

Table 46. Italy Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Online Pharmacies

Table 47. Spain Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn) – Disease Indication

Table 48. Spain Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn) – Autoimmune Diseases

Table 49. Spain Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Route of Administration

Table 50. Spain Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Drug Class

Table 51. Spain Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Distribution Channel

Table 52. Spain Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Hospital Pharmacies

Table 53. Spain Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Compounding Pharmacies

Table 54. Spain Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Retail Pharmacies

Table 55. Spain Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn) – Online Pharmacies

Table 56. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn) – Disease Indication

Table 57. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn) – Autoimmune Diseases

Table 58. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn)

– Route of Administration

Table 59. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn)

– Drug Class

Table 60. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn)

– Distribution Channel

Table 61. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn)

– Hospital Pharmacies

Table 62. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn)

– Compounding Pharmacies

Table 63. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn)

– Retail Pharmacies

Table 64. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US\$ Mn)

– Online Pharmacies

Table 65. Recent Inorganic Growth Strategies in the Biosimilars Market

Table 66. Recent Organic Growth Strategies in Biosimilars Market

Table 67. Glossary of Terms

## List Of Figures

### LIST OF FIGURES

Figure 1. Biosimilars Market Segmentation

Figure 2. Biosimilars Market, by Region

Figure 3. Key Insights

Figure 4. Europe: PEST Analysis

Figure 5. Europe Biosimilars Market- Key Industry Dynamics

Figure 6. Europe Biosimilars Market: Impact Analysis of Drivers and Restraints

Figure 7. Europe Biosimilars Market – Revenue Forecast and Analysis – 2020–2030

Figure 8. Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)

Figure 9. Cancer: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 10. Diabetes: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 11. Autoimmune Diseases: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 12. Psoriasis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 13. Arthritis: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 14. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 15. Other Disease Indication: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 16. Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)

Figure 17. Intravenous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 18. Subcutaneous: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 19. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 20. Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)

Figure 21. Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 22. Insulin: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 23. TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market –

Revenue and Forecast to 2030 (US\$ Million)

Figure 24. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 25. Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)

Figure 26. Hospital Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 27. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 28. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 29. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 30. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 31. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 32. Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 33. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 34. Compounding Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 35. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 36. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 37. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 38. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 39. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 40. Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 41. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 42. Retail Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)



Figure 43. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 44. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 45. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 46. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 47. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 48. Retina Specialists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 49. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 50. Online Pharmacies: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 51. Endocrinologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 52. Immunologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 53. Rheumatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 54. Oncologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 55. Dermatologists: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 56. Retina Compounding: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 57. Others: Europe Biosimilars Market – Revenue and Forecast to 2030 (US\$ Million)

Figure 58. Europe Biosimilars Market, By Region, 2022 (\$Mn)

Figure 59. Europe Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn)

Figure 60. Europe Biosimilars Market, By Key Countries, 2022 And 2030 (%)

Figure 61. Germany Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn)

Figure 62. UK Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn)

Figure 63. France Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn)

Figure 64. Italy Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn)

Figure 65. Spain Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn)

Figure 66. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US\$ Mn)

Figure 67. Pre and Post COVID-19 Impact on Europe Biosimilars Market

Figure 68. Growth Strategies in Biosimilars Market



## I would like to order

Product name: Europe Biosimilars Market Forecast to 2030 - Regional Analysis By Disease Indication (Cancer, Diabetes, Autoimmune Disease, and Other Disease Indication), Route of Administration (Intravenous, Subcutaneous, and Others), Drug Class (Granulocyte Colony-Stimulating Factor, Insulin, TNF Blockers and Monoclonal Antibodies, and Others), Distribution Channel (Hospital Pharmacies, Compounding Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region

Product link: <https://marketpublishers.com/r/E146EE1D1C50EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E146EE1D1C50EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970